<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659657</url>
  </required_header>
  <id_info>
    <org_study_id>2016PHB006-01</org_study_id>
    <nct_id>NCT02659657</nct_id>
  </id_info>
  <brief_title>Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation</brief_title>
  <official_title>Prophylaxis Roles of Low Dose of IL-2 Treatment on GVHD After Haploidentical Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow&#xD;
      transplantation (HBMT) on hematological malignancies are well established.The aim of this&#xD;
      prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be&#xD;
      decreased with IL2 therapy post HBMT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow&#xD;
      transplantation (HBMT) on hematological malignancies are well established.The aim of this&#xD;
      prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be&#xD;
      decreased with IL2 therapy post HBMT.low dose of IL-2 (40 million U/m2) will be administered&#xD;
      from WBC engraftment to day 90 post haploidentical transplantation. IL-2 will be administered&#xD;
      three times a week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>II-IV acute graft-versus-host disease (aGVHD) post transplantation</measure>
    <time_frame>Day 100 post transplantation</time_frame>
    <description>cumultive incidence of II-IV acute graft-versus-host disease (aGVHD) post transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe chronic GVHD post transplantation</measure>
    <time_frame>1 year post transplantation</time_frame>
    <description>cumulative incidence of severe chronic GVHD post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV infection post transplantation</measure>
    <time_frame>Day 100 post transplantation</time_frame>
    <description>cumulative incidence of CMV infection post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measureable residual disease (MRD)-positive test post transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>cumulative incidence of MRD+ post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological relapse post transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Cumulative incidence of hematological relapse post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free free survival post transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Cumulative incidence of DFS post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival post transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Cumulative incidence of OS post transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Acute Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Interleukin-2 interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)</description>
    <arm_group_label>Interleukin-2 interventions</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 15-65 years old&#xD;
&#xD;
          2. Acute leukemia in complete remission (CR1/CR2) who received myeloablative&#xD;
             haploidentical allo-HSCT&#xD;
&#xD;
          3. WBC engraftment (ANC&gt;500/ul for continuous 3 days)&#xD;
&#xD;
          4. At least +7d&#xD;
&#xD;
          5. Less than or equal to +15d&#xD;
&#xD;
          6. non T-ALL&#xD;
&#xD;
          7. no active II-IV aGVHD&#xD;
&#xD;
          8. no severe infections&#xD;
&#xD;
          9. Karnofsky score greater than or equal to 90%&#xD;
&#xD;
         10. Haploidentical donor from sibling, children or father&#xD;
&#xD;
         11. Ensure that informed consent signed and faxed to Research Coordinator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Exposure to any other clinical trials prior to enrollment&#xD;
&#xD;
          2. Active malignant disease relapses or MRD positive&#xD;
&#xD;
          3. Active, uncontrolled infection&#xD;
&#xD;
          4. Inability to comply with IL-2 treatment regimen&#xD;
&#xD;
          5. Active, uncontrolled II-IV aGVHD&#xD;
&#xD;
          6. Haploidentical donor from mother or collateral donors&#xD;
&#xD;
          7. Clinical Signs of severe pulmonary dysfunction&#xD;
&#xD;
          8. Clinical Signs of sever cardiac dysfunction&#xD;
&#xD;
          9. Receiving corticosteroids as GVHD treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Intitute of Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangyu Zhao</last_name>
    <phone>+861088324576</phone>
    <email>zhao_xy@bjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaosu Zhao</last_name>
    <phone>+861088324576</phone>
    <email>zhao.xiaosu@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangyu Zhao, M.D., PhD</last_name>
      <phone>+861088325949</phone>
      <email>xyz80421@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang,MD</investigator_full_name>
    <investigator_title>Chief of Peking University Institute of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

